The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance
Abstract
Multidrug resistance (MDR) is frequently associated with overexpression of a 170-kDa P-glycoprotein (Pgp). Data suggest altered protein kinase C (PKC) activity in cells expressing the multidrug-resistant phenotype. The staurosporine derivative CGP 41251, an experimental anticancer drug, has been shown to exert selectivity for inhibition of protein kinase C activity and to exhibit antitumor activity in vitro and in vivo. Here we show that CGP 41251 is also able to reverse MDR. After treatment of the multidrug-resistant human lymphoblastoid cell line CCRF-VCR1000 with 500 nM Adriamycin, cell proliferation was reduced to 81% of untreated controls. A combination of 500 nM Adriamycin with a non-toxic concentration of 150 nM CGP 41251 (IC50 for inhibition of cell proliferation 420 nM CGP 41251) inhibits cell proliferation of CCRF-VCR1000 cells to 29% of untreated controls. In sensitive CCRF-CEM cells no enhancement of Adriamycin-induced cytotoxicity was observed upon addition of 150 nM CGP 41251. Strong synergism of the inhibition of cell proliferation was also observed after concomitant treatment of KB-8511 cells with CGP 41251 and Vinblastine or Adriamycin. Drug-sensitive KB-31 cells could not be further sensitized to Adriamycin or Vinblastine with CGP 41251 doses above 100 nM. Pretreatment with 50-1000 nM CGP 41251 for 30 min led to a dose-dependent increase in the intracellular accumulation of rhodamine 123, a substrate of P-glycoprotein. Treatment of multidrug-resistant CCRF-VCR1000 cells with CGP 41251 for 10 min was sufficient to inhibit the efflux of rhodamine 123. Preincubation with CGP 41251 for 12 or 24 hr did not alter multidrug resistance gene (mdrI)-mRNA levels. CGP 41251, a drug with antitumor efficacy in experimental systems, might offer an attractive combination partner for the treatment of tumors expressing the MDR phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides activators, CGP 41251, an inhibitor of PKC, has also shown anti‐tumor activity and was found to reverse multidrug resistance when combined with adriamycin [130].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [130]
In the citing paper
“Besides activators, CGP 41251, an inhibitor of PKC, has also shown anti‐tumor activity and was found to reverse multidrug resistance when combined with adriamycin [130].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [130]
Citations
Cites
1 retracted
Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Röusel, J., Möller, M., Caravatti, G., & Matter, A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430519 · Cited by 407
Self-citationRetractedA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
The regulation of transcription by phosphorylation
Hunter, T., & Karin, M. (1992) · Cell · doi:10.1016/0092-8674(92)90162-6 · Cited by 1,281
Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7160 · Cited by 714
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1982) · PubMed · Cited by 659
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.
Gottesman, M. M. (1993) · PubMed · Cited by 352
Use of fluorescent dyes as molecular probes for the study of multidrug resistance
Neyfakh, A. A. (1988) · Experimental Cell Research · doi:10.1016/0014-4827(88)90152-8 · Cited by 246
Phorbol esters induce multidrug resistance in human breast cancer cells.
Fine, R. L., Patel, J., & Chabner, B. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.582 · Cited by 238
Research works printed but not linked: 5
- Benson A. B., 1985, Phase I study of vinblastine and verapamil given hy concurrent iv infusion, Cancer Treat. Rep., 69, 795
- Chaudhary P. M., 1992, Activation of MDRI (P‐ glycoprotein) gene expression in human agonists, Oncology Res., 4, 281
- Dong Z., 1991, In vitro model for intrinic drug resistance: effects of protein kinnse C activators on chemosensitivity of cultured human colon cancer cells, Mol. Phannacol., 19, 563
- Fidler I. J., 1993, Role of the organ environment in the pathogenesis of cancer metastasis, Proc. Amer. Assoc. Cancer Res., 34, 570
- Matter A., 1991, A pharmacological approach to growth regulation of breast cancer cells, Pezcoller Foundation Symp., 2, 227
Cited by
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
The potential for isoenzyme‐selective modulation of protein kinase C
Hofmann, J. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.8.9240967 · Cited by 340
Self-citationTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1485 · Cited by 233
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Staurosporine, a Potentially Important Gift from a Microorganism.
OMURA, S., SASAKI, Y., IWAI, Y., & TAKESHIMA, H. (1995) · The Journal of Antibiotics · doi:10.7164/antibiotics.48.535 · Cited by 216
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
Signal-Transduction Therapy. A Novel Approach to Disease Management
Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.000t1.x · Cited by 212
Fabbro, D., Buchdunger, E., Wood, J., Mestan, J., Hofmann, F., Ferrari, S. M., Mett, H., O’Reilly, T., & Meyer, T. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00005-4 · Cited by 145
Novel Targets for Lung Cancer Therapy: Part I
Dy, G. K., & Adjei, A. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.145 · Cited by 139
Palanisamy, S. K., Rajendran, N. M., & Marino, A. (2017) · Natural Products and Bioprospecting · doi:10.1007/s13659-016-0115-5 · Cited by 133
Classical PKC isoforms in cancer
Martiny‐Baron, G., & Fabbro, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.001 · Cited by 129
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 136
ATP site-directed competitive and irreversible inhibitors of protein kinases
Garc�a-Echeverr�a, C., Traxler, P. M., & Evans, D. B. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<28::aid-med2>3.0.co;2-2 · Cited by 124
Gekeler, V., Boer, R., Überall, F., Ise, W., Schubert, C., Utz, I., Hofmann, J., Sanders, K. H., Schächtele, C., Klemm, K., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.454 · Cited by 116
Self-citationProtein kinase C: a target for anticancer drugs?
MacKay, H. J., & Twelves, C. J. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100389 · Cited by 104
Staurosporine analogues — pharmacological toys or useful antitumour agents?
Gescher, A. J. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00058-5 · Cited by 103
Gescher, A. J. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00069-x · Cited by 94
Multidrug resistance of cancer cells
Kane, S. E. (1996) · Advances in Drug Research · doi:10.1016/s0065-2490(96)80005-0 · Cited by 91
Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites?
Das, U. N., Madhavi, N., Kumar, G. S., Padma, M., & Sangeetha, P. (1998) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(98)90128-4 · Cited by 82
Courage, C., Budworth, J., & Gescher, A. J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.137 · Cited by 76
Modulation of protein kinase C in antitumor treatment
Hofmann, J. (2008) · Springer eBooks · doi:10.1007/bfb0117491 · Cited by 79
Self-citationGill, P. K., Gescher, A. J., & Gant, T. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02326.x · Cited by 65
Budworth, J., Davies, R., Malkhandi, J., Gant, T. W., Ferry, D. R., & Gescher, A. J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.205 · Cited by 64
Potentiation by Thyroid Hormone of Human IFN-γ-Induced HLA-DR Expression
Lin, H., Martino, L. J., Wilcox, B. D., Davis, F. B., Gordinier, J., & Davis, P. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.843 · Cited by 56
Millward, M. J., House, C. M., Bowtell, D. D. L., Webster, L. K., Olver, I., Gore, M. E., Copeman, M. C., Lynch, K., Yap, A., Wang, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603331 · Cited by 54
GANESHAGURU, K., Wickremasinghe, R. G., Jones, D. T., Gordon, M., Hart, S., Virchis, A. E., Prentice, H. G., Hoffbrand, A. V., Man, A., Champain, K., et al. (2002) · PubMed · Cited by 52
Thavasu, P., PROPPER, D. J., McDonald, A. C., Dobbs, N. A., Ganesan, T. S., Talbot, D., Braybrook, J., Caponigro, F., Hutchison, C., Twelves, C., et al. (1999) · PubMed · Cited by 51
Bioactive Natural Products from Marine Invertebrates and Associated Fungi
Proksch, P., Ebel, R., Edrada‐Ebel, R., Wray, V., & Steube, K. G. (2003) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-55519-0_5 · Cited by 47
Harkin, S. T., Cohen, G. M., & Gescher, A. J. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13067-2 · Cited by 42
Protein Kinase C: An Attractive Target for Cancer Therapy
Marengo, B., Ciucis, C. D., Ricciarelli, R., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2011) · Cancers · doi:10.3390/cancers3010531 · Cited by 41
Virchis, A. E., GANESHAGURU, K., Hart, S., Jones, D. T., Fletcher, L., Wright, F., Wickremasinghe, R. G., Man, A., Csermak, K., Meyer, T., et al. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200165 · Cited by 39
Schupp, P. J., Steube, K. G., Meyer, C., & Proksch, P. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00694-2 · Cited by 38
Ohtani, K., Sakamoto, H., Kikuchi, A., Nakayama, Y., Idei, T., Igarashi, N., Matukawa, T., & Satoh, K. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00713-8 · Cited by 37
Budworth, J., Gant, T. W., & Gescher, A. J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.225 · Cited by 36
Beltran, P. J., Fan, D., Fidler, I. J., & O’Brian, C. A. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00718-6 · Cited by 32
Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells
Courage, C., Snowden, R. T., & Gescher, A. J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.517 · Cited by 31
Decreased potency of MDR‐modulators under serum conditions determined by a functional assay
Ludescher, C., Eisterer, W., Hilbe, W., Hofmann, J., & Thaler, J. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05362.x · Cited by 30
Self-citationMidostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
Ji, N., Yang, Y., Cai, C., Wang, J., Lei, Z., Wu, Z., Cui, Q., Yang, D., Chen, Z., & Kong, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00514 · Cited by 29
Schlenk, R. F., & Käyser, S. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_10 · Cited by 28
Further Minor Metabolites of Staurosporine Produced by a Streptomyces longisporofiavus Strain.
CAI, Y., Fredenhagen, A., Hug, P., Meyer, T., & PETER, H. H. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.519 · Cited by 27
Midostaurin treatment inFLT3-mutated acute myeloid leukemia and systemic mastocytosis
Käyser, S., Levis, M. J., & Schlenk, R. F. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1387051 · Cited by 26
Tvedt, T. H. A., Nepstad, I., & Bruserud, Ø. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1275564 · Cited by 25
Protein kinases and multidrug resistance
Rumsby, M. G., Drew, L., & Warr, J. R. (1998) · Cytotechnology · doi:10.1023/a:1008073006495 · Cited by 22
Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700
Utz, I., Spitaler, M., Rybczyńska, M., Ludescher, C., Hilbe, W., Regenass, U., Grunicke, H. H., & Hofmann, J. (1998) · International Journal of Cancer · Cited by 22
Self-citationProtein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response
Aquino, A., Bianchi, N., Terrazzan, A., & Franzese, O. (2023) · Biology · doi:10.3390/biology12081047 · Cited by 24
Courage, C., Bradder, S. M., Jones, T., Schultze‐Mosgau, M., & Gescher, A. J. (1997) · International Journal of Cancer · Cited by 20
A novel bioassay for P-glycoprotein functionality using cytochalasin D
Elbling, L., Berger, W., Weiss, R.-M., Printz, D., Fritsch, G., & Micksche, M. (1998) · Cytometry · Cited by 19
Sedlák, J., Hunáková, Ľ., Sulíková, M., & Chorvath, B. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00088-4 · Cited by 17
Ohmori, T., & Arteaga, C. L. (1998) · PubMed · Cited by 16
Estupiñán, Ó., Santos, L. M., Rodríguez, A., Fernández‐Nevado, L., Costales, P., Pérez‐Escuredo, J., Hermosilla, M. A., Oro, P., Rey, V., Tornín, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32081 · Cited by 15
3‐Aminobenzamide inhibition of protein kinase C at a cellular level
Ricciarelli, R., Palomba, L., Cantoni, O., & Azzi, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00811-4 · Cited by 14
Reversal of MDR by Verapamil Analogues
Grossi, A., & Biscardi, M. (2004) · Hematology · doi:10.1080/10245330310001639009 · Cited by 12
Yoshikawa, N., Nakamura, K., Yamaguchi, Y., Kagota, S., Shinozuka, K., & Kunitomo, M. (2003) · Life Sciences · doi:10.1016/s0024-3205(02)02407-4 · Cited by 12
The role of protein kinase C in nicotinic responses of bovine chromaffin cells
Loneragan, K., Cheah, T. B., Bunn, S. J., & Marley, P. D. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00397-4 · Cited by 11
Damiens, E. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_19 · Cited by 10
Raffaniello, R. D., Nam, J., Cho, I., Lin, J., Bao, L., Michl, J., & Raufman, J. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8579 · Cited by 10
Natural Products in Polyclad Flatworms
McNab, J. M., Rodríguez, J., Karuso, P., & Williamson, J. E. (2021) · Marine Drugs · doi:10.3390/md19020047 · Cited by 8
Duraj, J., Kovacikova, M., Sedlák, J., Koppel, J., Sobel, A., & Chorvath, B. (1995) · Leukemia Research · doi:10.1016/0145-2126(94)00154-3 · Cited by 8
Akan, E., Chang‐Liu, C., Watanabe, J., Ishizawa, K., & Woloschak, G. E. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00125-7 · Cited by 7
Development of Midostaurin as a Tyrosine Kinase Inhibitor
Motyckova, G., & Stone, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_10 · Cited by 5
van Gijn, R., Havik, E., Boven, E., Vermorken, J. B., Huinink, W. W. T. B., van Tellingen, O., & Beijnen, J. H. (1995) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(95)01616-3 · Cited by 5
Chorvath, B., Sedlák, J., & Novotn, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590624 · Cited by 4
Protein kinases and multidrug resistance
Rumsby, M. G., Drew, L., & Warr, J. R. (1998) · Springer eBooks · doi:10.1007/978-94-017-2374-9_13 · Cited by 4
Inhibition of aldosterone biosynthesis by staurosporine
Bureik, M., Mion, A., Kenyon, C. J., & Bernhardt, R. (2005) · Biological Chemistry · doi:10.1515/bc.2005.077 · Cited by 3
FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Baer, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00006-7 · Cited by 2
Promising Developments in Targeted Therapies for non–small-Cell Lung Cancer
Hao, D., & Hidalgo, M. M. (2002) · Clinical Lung Cancer · doi:10.3816/clc.2002.n.021 · Cited by 2
Natural Compounds as Specific Inhibitors of Cyclin-Dependent Kinases – Past, Present and Future
Maurer‐Granofszky, M., Komina, O., & Węsierska‐Gądek, J. (2012) · Springer eBooks · doi:10.1007/978-94-007-4575-9_14
Signal-transduction therapy: A novel approach to disease management
Levitzki, A. (1994) · Springer eBooks · doi:10.1007/978-3-642-79502-2_15
Metadata
- Authors
- Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., & Hofmann, J.
- Affiliations
- Universität Innsbruck (AT)
- Corresponding author
- Hofmann, Johann
- ORCID
- Hofer, Susanne
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-04
- Volume
- 57
- Issue
- 1
- Pages
- 104-110
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2057939330
- Cited by
- 72
- References
- 36
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 1 · 2014: 2 · 2012: 1
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- staurosporine derivatives, PKC inhibitors, multidrug resistance reversal, P-glycoprotein, multidrug resistance gene 1, doxorubicin, vinblastine, drug efflux inhibition, rhodamine 123 accumulation, synergistic drug combination, lymphoblastoid cell lines, MDR1 mRNA
- MeSH terms
- Alkaloids, Antineoplastic Agents, Carrier Proteins, Doxorubicin, Drug Resistance, Humans, KB Cells, Lymphocytes, Membrane Glycoproteins, Protein Kinase C, Rhodamines, Tumor Cells, Cultured, Vincristine, Gene Expression, Staurosporine, Rhodamine 123, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.